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The clinical use of pig lungs for human allodonationsis limited by the hyperacute rejection,1 the hallmark
of xenograft dysfunction in such discordant transplants
as the pig to human combination. This process results
from the binding of human natural antibodies to the
porcine endothelium, which in turn activates the com-
plement cascade, inducing endothelial injury, pul-
monary edema, thrombosis of the pulmonary microcir-
culation, increase in pulmonary vascular resistance
(PVR), and loss of xenograft function within 1 to 2
hours of revascularization.2-4
With the increasing understanding of its pathophysiolo-
gy,5,6 2 basic strategies to prevent lung hyperacute rejec-
tion have emerged: (1) depletion of human natural
xenoantibodies2,7 and (2) inhibition of complement acti-
vation.4,8 Whereas experiments with pigs transgenic for
complement regulatory proteins4,8 or selective pharmaco-
logic blockage of complement2,9 demonstrated incom-
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plete physiologic protection, Daggett and associates7 pro-
vided recent evidence that pretransplantation pig lung
perfusion prevented pig to primate pulmonary xenograft
rejection. Unfortunately, the exact mechanisms responsi-
ble for this effect were not elucidated. To test the hypoth-
esis that the anti-a -galactosyl (anti-a -Gal) xenoantibod-
ies may not be the only human molecules triggering pig
lung hyperacute rejection,10 human blood was immuno-
absorbed either through pig donor organs (lung, liver,
spleen) or a -galactosyl (a -Gal) columns and subsequent-
ly used to perfuse an ex vivo pig lung working model.
Materials and methods
Animals and study design. Large White outbred pigs
weighing between 20 and 30 kg served as lung donors. All
animals received care in compliance with the “Principles of
Laboratory Animal Care” formulated by the National Society
for Medical Research and the “Guide for the Care and Use of
Laboratory Animals” formulated by the National Academy of
Sciences (NIH publication no 85-23, revised 1985). Human
blood was obtained from informed patients (Claude Huriet
Law, No 88-1138, 20 December 1988 [French law]) under-
going therapeutic phlebotomies for hemochromatosis, col-
lected at the Blood Banks of the West Île-de-France Public
Interest Group, and screened for viral-transmitted diseases.
Each blood unit (approximately 400 mL) was anticoagulated
with 1.2 U/mL heparin and used within 30 days.
Four experimental groups were randomly studied. The
human blood was absorbed in situ through isolated pig donor
right lung (group I), liver (group II), or spleen (group III), or
was absorbed in vitro (human plasma) through an a -Gal col-
umn (group IV). The collected or reconstituted human blood
was then used to perfuse ex vivo the left lungs taken from the
same pig donors until the onset of rejection. Each study group
included 6 animals. Blood samples were taken at baseline and
after 10, 30, 60, 90, 120, and 180 minutes of reperfusion and
were subsequently stored in aliquots at –80°C until use.
In situ pig organ perfusion. Animals were medicated
before the experiment with intramuscular ketamine hydro-
chloride (25 mg/kg) and atropine sulfate (1 mg/kg) and were
anesthetized with intravenous sodium pentobarbital (25
mg/kg). After orotracheal intubation, anesthesia was main-
tained with inhaled halothane and the animals received
mechanical ventilation (Labaz Inc Ventilator, Chemin Cami-
Saliè, Pau, France) with an equal gas mixture of oxygen and
protoxide. Ear venous catheters were placed for infusion of
crystalloid solutions; adequacy of ventilation and adequacy
of oxygenation were assessed by arterial blood gas analysis
and pulse oximetry. After completion of a median sternotomy
and upper laparotomy, the abdominal viscera were lifted
away from the diaphragm to avoid compression of the lower
lung lobes and the anterior pericardium was opened and sus-
pended. The isolated organs were perfused with an infusing
arterial cannula (William Harvey, CR Bard, Inc, Billerica,
Mass), with a single passage of human blood (initial total vol-
832 Macchiarini et al The Journal of Thoracic and
Cardiovascular Surgery
November 1998
Fig 1. Surgical isolation of pig donor right lung (A) and liver (B).
ume approximately 400 mL). A venting cannula (William
Harvey) drained the passed human blood into plastic bags
(Maco Pharma, Tours, France).
In group I a single circular purse-string suture of 4-0
polypropylene (Prolene; Ethicon, Inc, Somerville, NJ) was
placed in the pulmonary artery trunk for insertion of a 14F
arterial cannula; a second suture with several polytetrafluo-
roethylene (Teflon) felt pledgets was placed on the tip of the
left ventricle for insertion of a 20F venting atrioventricular
cannula. After systemic heparinization (3 mg/kg) and topical
electrically induced cardiac arrest, the origin of the ascending
aorta and pulmonary trunk were crossclamped and both lungs
preserved by Euro-Collins solution (ECS; total volume 65
mL/kg at 4°C at a perfusion pressure of 80 mm Hg) infused
and drained through the arterial and venting cannulas; the
right atrium was opened to decompress the right heart cham-
bers. After completion of the perfusate, the right lungs were
isolated by (1) crossclamping the origin of the left pulmonary
artery and left atrium beyond the orifices of the left pul-
monary veins, (2) ligating the infracardiac lobe vessels, and
(3) clamping (in inflation) the left main bronchus after devel-
opment of the posterior pericardium. The right lungs were
then perfused (perfusion pressure 80 mm Hg) with a human
blood unit with the arterial and venting cannulas (Fig 1, A).
In group II the infracardiac pleural space was opened and the
inferior vena cava (IVC) was dissected from its entry into the
right atrium up to its suprahepatic veins origin after perpendic-
ular and midline division of the diaphragmatic muscle. The
hepatic artery and choledochal duct were then ligated at the
hepatic ligament above the second portion of duodenum to
allow exposure of the portal vein, which was subsequently can-
nulated at its origin with a 21F arterial cannula inserted
through a circular purse-string 4-0 Prolene suture. The right
hepatic lobes (medial, lateral, and caudal) were then lifted on
the left and the right diaphragmatic crus was opened to expose
the infrahepatic IVC, which was encircled with a tourniquet. A
14F venting cannula was then inserted through a purse-string
4-0 Prolene suture into the suprahepatic IVC. After systemic
heparinization (3 mg/kg) and topical electrically induced car-
diac arrest, the lungs were flushed with ECS as for group I ani-
mals. Total vascular liver exclusion was then obtained by lig-
ating the suprahepatic IVC at its entrance into the right atrium
and the origin of the infrahepatic IVC, and by division of the
coronary and triangular ligaments. After ligation of the origin
of the portal vein, the liver was flushed with 2 L 4°C ECS (per-
fusion pressure 100 mm Hg) through the previously placed
cannulas. Thereafter the liver was perfused with the human
blood unit through the same closed circuit (Fig 1, B).
In group III animals the splenic artery and vein were dis-
sected and cannulated with a 12F arterial cannula and a 14F
venting cannula placed through 2 purse-string circular 5-0
Prolene sutures. After systemic heparinization (3 mg/kg) and
topical electrically induced cardiac arrest, both lungs were
flushed with ECS as described previously. The spleens were
isolated by ligating the splenic artery and veins beyond their
cannulas and were perfused with 2 L 4°C ECS first and then
with human blood.
In vitro a -Gal immunoabsorption of human plasma.
Spacered Gala (1-3)Gal disaccharide haptens were produced
by chemical synthesis11 and covalently coupled to a flexible,
hydrophilic polymer (poly N-hydroxyethylacrylamide; PAA)
of approximately 35 kDa.12,13 The PAA–a -Gal conjugates
were covalently coupled to Sepharose 6 FF (Pharmacia Bio-
tech, Export GmbH, Vienna, Austria). The resulting a -Gal
immunoabsorbent is mechanically and chemically stable and
can be sterilized with formaldehyde.
Chromatographic columns 2.5 cm in diameter (Econo col-
umn; BioRad, Richmond, Calif) were packed with approxi-
mately 50 mL of the a -Gal immunoabsorbent and connected
to a peristaltic pump at a flow rate of about 4 mL/min. The
columns were rinsed with 250 mL phosphate-buffered saline
solution (PBS), pH 7.4, and subsequently with 250 mL 5%
human serum albumin (albumin SRK; Central Laboratory,
Swiss Red Cross, Bern, Switzerland). The pump was then
turned off and the column was incubated with the human
serum albumin solution for about 2 hours at room tempera-
ture. After rinsing with another 100 mL 5% human serum
albumin, the column was immediately used for antibody
absorption. Each human blood unit was separated into formed
elements and plasma by centrifugation for 15 minutes at
3000g. The blood cells were washed with PBS (15 minutes,
3000g) to remove remaining plasma. The plasma itself
(approximately 220 mL) was absorbed on the a -Gal column
(group IV). Absorbed plasma and washed blood cells were
then mixed, and this anti-a -Gal–depleted human reconstitut-
ed whole blood was used for the ex vivo pig left lung perfu-
sion experiments. After absorption the column was regenerat-
ed as follows: rinsing with 400 mL PBS, acid elution of bound
antibodies with 300 mL 0.1 mol/L glycine hydrochloride, pH
2.3, rinsing again with 400 mL PBS and subsequently with
200 mL 2% formaldehyde solution in PBS for sterilization,
and storage of immunoabsorption material in the formalde-
hyde solution until further use.
Harvest technique. On completion of the in situ pig organ
or in vitro column perfusion, pig left lungs were removed.
Care was taken to have the maximum length of the left pul-
monary artery and main bronchus and a large cuff of left atri-
um incorporating the 3 to 4 left pulmonary veins and the
venous return from the infracardiac lobe of the right lung. A
4-0 Prolene purse-string suture was placed on the free cuff
walls of the left atrium. The grafts were then placed inflated
in 2 sterile plastic bags containing cold (4°C) ECS.
Before the ex vivo experiments, a 3⁄8-inch straight tube con-
nector (Dideco Inc, Mirandola, Italy) was placed in the left
pulmonary artery for pulmonary artery inflow, another was
placed in the left main bronchus for mechanical ventilation,
and another was placed in the cuff of the left atrium to pas-
sively drain pulmonary vein blood outflow. Ligatures were
then tied around the cannulas.
Ex vivo pig-to-human lung xenograft model. The ex vivo
lung perfusion and ventilation model was used as described
previously.3 In brief, left lungs suspended by the left main
bronchus connectors in a thermostatically controlled, humidi-
fied chamber were continuously ventilated with room air
The Journal of Thoracic and
Cardiovascular Surgery
Volume 116, Number 5
Macchiarini et al   833
(inspired oxygen fraction 0.21) by a mechanical ventilator
(Siemens-Elema, Solna, Sweden) at a tidal volume of 200 mL
at 20 breaths/min with 5 cm H2O positive end-expiratory pres-
sure and perfused with autogenic undiluted pig blood for the
first 30 minutes in all groups to obtain adequate stabilization.
Before reperfusion with human blood, pig lungs were flushed
with 1.5 L saline solution to avoid any hemolysis. Next, lungs
were continuously ventilated with a 75% nitrogen, 20% oxy-
gen, and 5% carbon dioxide gas mixture and perfused through
the inflow and outflow connectors attached to the blood-
primed perfusion circuit through silicone tubing (Bentley
ByPass 70-tubing, Bentley Laboratories, Inc, Irvine, Calif).
Venous blood return was collected through the outflow can-
nula into the oxygenator cardiotomy reservoir, continuously
deoxygenated (93% nitrogen, 5% carbon dioxide, and 2%
oxygen) with a neonatal oxygenating system (Polystan Safe
Micro; Polystan, Copenhagen, Denmark), and returned to the
left pulmonary artery through a roller pump (Ismatec mod;
Bioblock, Strasbourg, France) at a flow rate of 100 mL/min.
The residual human blood volume after this preperfusion was
approximately 300 mL. The total initial volume of heparinized
(0.15 mL/kg) blood perfusing the ex vivo circuit was limited
to 200 mL blood, and further blood was added thereafter. A
heater (HAAKE FK/F4391; Gebruder Haake GmbH, Berlin,
Germany) warmed the humidified chamber and blood to
37°C. Perfusion pressure was continuously monitored with a
pressure transducer (Gould Electronics BV, Bilthoven, The
Netherlands) placed in series with the perfusion inflow line.
The perfusion flow rate was manually adjusted to maintain a
constant perfusion pressure of 10 mm Hg. During reperfusion,
pH and sodium, potassium, magnesium, and calcium ions
were monitored and adjusted to maintain physiologic values.
Functional measurements. Arterial and venous blood
samples were collected for blood gas analysis (ABL3; Radi-
ometer, Copenhagen, Denmark) and hematocrit evaluation
(Cellokrit; AB Lar Lyunberg, Stockholm). Blood electrolytes
and pH adjustments were made as needed during the study
period to maintain physiologic arterial blood pH (7.3-7.4).
Arterial samples were taken from the left atrium outflow can-
nula and venous samples were taken from blood exiting
directly from the oxygenator. The arteriovenous oxygen con-
centration difference (CaO2 – CvO2 in milliliters of oxygen
per 100 mL blood) was calculated as follows:
CaO2 – CvO2 = [(1.34 · Hb) · (SaO2)] – [(1.34 · Hb) · (SvO2)]
where S is the arterial (SaO2) or venous (SvO2) oxygen sat-
uration and Hb is hemoglobin concentration (in grams per
deciliter).
The PVR (in millimeters of mercury per milliliter per
minute) was calculated from measurements of the blood flow
with a flow probe (Statham SP2202; Statham, Inc,
Biomedical Division, Oxnard, Calif) and the pulmonary
artery pressure (PAP in millimeters of mercury; Kipp and
Zonen, Solingen, Germany) and calculated as follows:
Complement activity. A quantitative assay was used to
detect complement activity of the human blood, (Kallestad
Quantiplate; Sanofi Diagnostics Pasteur SA, Paris, France).
In brief, human serum was placed in wells and diffused
through an agarose gel medium containing standardized
sheep erythrocytes sensitized with hemolysin. Total comple-
ment activity (CH100) was subsequently estimated by com-
paring the extent of the lysis of the sheep erythrocytes caused
by the human serum to that caused by a standard reference
serum. By definition, 1 unit of complement (CH100) at pH
7.4, 37°C, in veronal buffer for 60 minutes will lyse 2 · 108
sheep erythrocytes sensitized with 2 U hemolysin. Pathologic
CH100 values are <70 CH100 U/mL.
Immunoglobulins, hemolysis, coagulations, and mem-
brane attack complex in human blood. Levels of total cir-
culating human immunoglobulin G (IgG), IgA, and IgM (in
grams per liter) were evaluated with class-specific antibodies
(Roche Diagnostics, Basel, Switzerland) and measured by
end-point turbidity at 340 nm. Lysis of red blood cells was
determined by measuring the absorbance of a diluted plasma
at 547 nm with reference to a standard curve of hemoglobin
and expressed as milligrams of hemoglobin per 100 mL.
Prothrombin time and activated partial thromboplastin time
were determined with a fibrin timer 10 semiautomatic device
(Behring Austria Diagnostica GmbH, Wien, Austria) by in
vitro activation (37°C) of plasma with human placental
thromboplastin (Thromborel S; Behring) and micronized silica
(automated activated partial thromboplastin time; Organon
Teknika BV, Turnhout, Belgium), respectively. Chronometric
determination of fibrinogen level (in grams per liter) was made
according to the Clauss method14 with an ST 888 semiauto-
matic device (Diagnostica-Stago, Ansieres, France) by in vitro
activation (37°C) of plasma with bovine thrombin (Fibromat;
BioMérieux, Lyon, France). The effects of heparin on the val-
ues of the activated partial thromboplastin time were evaluated
by the anti–factor Xa activity, which was kept below 0.5
U/mL.
The quantification of SC5b,6,7,8,9 (membrane attack com-
plex) in human serum was performed with the QUIDEL
SC5b,6,7,8,9 enzyme-linked immunosorbent assay (Quidel,
San Diego, Calif). Membrane attack complex is usually not
expressed in human serum.
Measurement of natural anti-a -Gal antibodies. Isotype-
specific determination of anti-a -Gal antibodies was per-
formed by enzyme-linked immunosorbent assay.15 In brief,
microtiter plates (NUNC Maxisorp; NUNC AB, Roskilde,
Denmark) were coated with soluble Bdi–PAA conjugates
(SYNTESOME GmbH, Munich, Germany). Coating condi-
tions were 4 m g/mL PAA-a -Gal in 0.1 mol/L carbonate
buffer, pH 9.6, overnight at 4°C. The plates were then washed
with PBS, pH 7.4, containing 0.02% polysorbate (Tween) 20.
The plasma samples were diluted 1:40 in PBS, pH 7.4, con-
taining 1% bovine serum albumin and 5% polysorbate 20 and
incubated at 100 m L/well for 2 hours at 37°C on a shaker.
After washing, bound anti-a -Gal antibodies were detected
with monoclonal antibodies to human IgG (clone 8a4), IgM
(AF6), or IgA (2D7). All monoclonal antibodies were mouse
IgG1 isotypes purchased from Oxoid (Basingstoke, Great






Britain). They were in turn revealed by biotinylated goat anti-
mouse IgG1 (SBA, Birmingham, Ala), streptavidin–alkaline
phosphatase conjugate (Amersham International, Amersham,
Great Britain), and 4-nitrophenyl-phosphate substrate. The
absorbance at 405 nm was measured with a microplate reader
(Dynatech, Alexandria, Va). Baselines of anti-a -Gal enzyme-
linked immunosorbent assay determinations were expressed
as a percentage of a standard serum (from a healthy blood
group O donor) included in each plate; their modifications
after the in situ, in vitro, and ex vivo perfusions were report-
ed as the percentage change from baseline.
Preparation of endothelial cell extracts. Porcine
endothelial cells were explanted from the aorta of Large
White pigs and cultured until confluence in Roswell Park
Memorial Institute medium containing 20% fetal calf serum
and 1 mmol/L sodium pyruvate.16 Endothelial cell monolay-
ers were washed, scraped from the flasks, and reduced to pel-
lets by centrifugation at 900g for 5 minutes. The cells were
resuspended and lysed in 1 volume of 50 mmol/L tris-
hydroxymethyl-amino methane (Tris, pH 7.2) containing 2%
t-octylphenoxypolyoxyethanol (Triton X-100), 5 mmol/L ethyl-
enediaminetetraacetic acid and Pefablock SC (Pentapliarm,
Basel, Switzerland), 1 mmol/L benzamidine, 15 m mol/L pep-
statin, and 10 m mol/L leupeptin for 30 minutes on ice. After
centrifugation at 10,000g for 30 minutes, the supernatant was
collected and stored at –70°C until used.
Sodium dodecyl sulfate–polyacrylamide gel and West-
ern blot analysis. Samples of endothelial cell extracts were
electrophoresed on a 7.5% gel under reducing conditions.
Proteins resolved in this way were transferred to 0.45-m m
polyvynillidene difluoride membranes,16 After saturation
with 3% low-fat dry milk in Tris-buffered saline solution
(TBS) overnight at 25°C, the membranes were washed 3
times with 0.3% polysorbate 20 in TBS and stored in this
buffer until used. Human serum samples were diluted 1:20 in
TBS and incubated overnight at 25°C. After washing with
0.3% polysorbate 20 in TBS, antibody binding was detected
by incubating blots with alkaline phosphatase–conjugated
affinity-purified m -chain–specific goat antihuman IgM or g -
chain–specific goat antihuman IgG (The Jackson Lab-
oratories, Bar Harbor, Me) diluted 1:1000 in 0.5% bovine
serum albumin in TBS for 2 hours at 25°C. The expression of
a -Gal residues was analyzed in parallel with either biotiny-
lated isolectin B4 from Griffonia simplicifolia (GSI-B4)16 or
a monoclonal antibody specific for Gal-a -(1,3)Gal diluted
1:4 in TBS and stained with alkaline phosphatase–conjugat-
ed affinity purified goat antimouse immunoglobulins (H+L;
Jackson). The immunoblots were revealed with the nitroblue
tetrazolium procedure (Biorad, Hercules, Calif).
Histologic examination. The in situ and ex vivo perfused
pig organs were assessed macroscopically. At least 4 samples
of representative areas were taken, and fragments were fixed
in 10% formaldehyde and routinely processed into paraffin
wax. Sections were cut at 5 µm and stained with hematoxylin
and eosin. Sections from paraffin blocks were also used for
immunohistochemical studies performed with the LSAB Kit
(Dako SA, Trappes, France). Rabbit antibodies were as fol-
lows: antihuman IgM and IgG diluted 1:1000 and anti-C3 di-
luted 1:30 (Biogenex-Menarini, Chevilly-Larue, Paris,
France).
Fresh tissue was snap-frozen in liquid nitrogen and stored
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Fig 2. Histologic signs of hyperacute rejections after in situ
perfusion of pig donor organs with human blood. A, Recent
fibrin and platelets thrombus (star) occluding the lumen of an
alveolocapillary vessel; arrows indicate platelets on the cap-
illary endothelium. B, Portal vein containing a recent throm-
bus made up by fibrin and platelets (star). The adjacent bil-
iary duct (arrow) and liver parenchyma are normal. C, Two
sections of a small artery in the white pulp of the spleen. The
lumen is occluded with fibrin and platelets, forming a throm-
bus. (Original magnification · 350.)
at –70°C. Immunostaining was carried out on cryostat sec-
tions by direct fluorescence. Fluorescein isothiocyanate-con-
jugated rabbit antibodies (Dako) were used diluted 1:10; anti-
human IgM, C1q, C3, and antifibrinogen or anti-IgG were
diluted 1:20.
Statistical analysis. All quantitative serum or plasma data
were normalized for hemodilution by correcting them for
changes in hematocrit value. Xenograft failure was defined as
such when the ex vivo lung perfusion was associated with no
gas exchange, severe pulmonary hypertension, and gross evi-
dence of pulmonary hemorrhage and edema. Experiments
were stopped at the occurrence of xenograft failure or at con-
sumption of the blood volumes (for functioning xenografts).
Data are expressed as mean ± standard deviation of the num-
ber of observations and analyzed by 1-way analysis of vari-
ance with the Fisher protected least significance difference.
Data were analyzed with a software package (STATVIEW
4.02; Abacus Concepts, Inc, Berkeley, Calif).
Results
In situ and in vitro absorption. All isolated pig donor
organs perfused in situ with human blood were hypera-
cutely rejected; they were congestive and hemorrhagic
and displayed fibrin and platelet thrombi obstructing the
alveolar capillaries, the portal sinuses, or the splenic
microvessels (Fig 2). Only pig livers showed infiltration
by inflammatory cells. The immunohistologic analysis of
these organs showed diffuse vascular staining of C1q,
C3, fibrinogen, and IgM.
After the in situ and in vitro perfusions, between 45%
and 93% of anti-a -Gal human antibodies were removed
from the human blood; a second marginal decline in the
anti-a -Gal xenoantibodies titers was observed 10 min-
utes after the ex vivo reperfusion but remained stable
thereafter (Table I). To compare the specificity of anti-
body depletion, the reactivity of human serum samples
was analyzed on porcine endothelial cell extracts before
and after pig organ or column adsorption. Before anti-
body depletion at least 10 bands corresponding to pro-
teins with apparent molecular weights of 250, 180, 160,
135, 110 to 120, 95, 80, 65 to 70, 45 to 50, and 25 to 35
kDa were revealed by human IgM and IgG (Fig 3, A and
B, lanes 1 and 3). The pattern of reactivity depended on
the serum used, but the most intensively reactive bands
generally migrated between 135 and 250 kDa. These
bands were also a -galactosylated, as assessed by GSI-
B4 lectin binding (data not shown) and anti-a -Gal mon-
oclonal antibody binding (Fig 3, A and B, lane 5). After
immunoadsorption on the a -Gal column, binding of
both IgG and IgM to the 135-kDa protein was removed,
whereas binding to other proteins remain unchanged
(Fig 3, A and B, lane 2). In contrast, after perfusion of
porcine lung antibody reactivities against the 135-kDa
protein but also against other proteins with lower molec-
ular weights of 30 to 34 and 26 kDa were lost, and anti-
body binding against proteins of 70 to 90 and of 45 to
55 kDa was decreased (Fig 3, A and B, lane 4). Similar
but weaker results were also observed after pig liver
perfusion (data not shown).
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Table I. Percentage decline from baseline values of anti-a -Gal xenoreactive antibodies in human blood during the
in situ, in vitro, and ex vivo experiments
Timing Right lung Liver Spleen a -Gal column
IgM anti-a -Gal Baseline 68 ± 26 (100%) 41 ± 13 (100%) 53 ± 24 (100%) 45 ± 14 (100%)
After 88 ± 6 72 ± 12 79 ± 9 93 ± 5
10 min 88 ± 5 77 ± 8 83 ± 6 97 ± 1
60 min 87 ± 6 77 ± 25 75 ± 15 94 ± 4
180 min 85 ± 10 80 ± 28 — —
IgG anti-a -Gal Baseline 68 ± 37 (100%) 42 ± 16 (100%) 106 ± 8 (100%) 21 ± 11 (100%)
After 93 ± 5 84 ± 18 91 ± 10 88 ± 13
10 min 96 ± 2 88 ± 13 96 ± 3 91 ± 11
60 min 97 ± 2 88 ± 10 96 ± 3 90 ± 10
180 min 96 ± 3 84 ± 15 — —
IgA anti-a -Gal Baseline 69 ± 17 (100%) 66 ± 38 (100%) 115 ± 52 (100%) 48 ± 23 (100%) 
After 77 ± 18 45 ± 25 83 ± 13 75 ± 19
10 min 87 ± 10 67 ± 24 83 ± 13 89 ± 7
60 min 91 ± 9 65 ± 25 87 ± 7 78 ± 10
180 min 85 ± 13 68 ± 25 — —
Results (mean ± standard deviation) are expressed as (1) baseline values of anti-a -Gal xenoreactive antibodies (compared to a standard serum) and (2) percentage
decline from baseline after in situ (pig donor organs) or in vitro (a -Gal column) absorption and after 10, 60 and 180 min of ex vivo lung perfusion. After in vivo or
in vitro absorption, the anti-a -Gal IgG and IgM were significantly better absorbed than anti-a -Gal IgA (P = .005) and the percentage of absorbed anti-a -Gal anti-
bodies was significantly higher (P = .02) after the in vitro than the lung but not spleen or liver in situ preperfusion. The liver absorbed in time a significantly lower
percentage of anti-a -Gal than the right lung (P = .04) and the a -Gal column (P = .001, IgM), the right lung (P = .01, IgG), and right lung (P < .0001), spleen
(P = .002), and the a -Gal column (P = .003, IgA).
Ex vivo lung perfusion. All group I xenografts were
functionally working after a median of 300 minutes
(range 240-360 minutes) of ex vivo reperfusion, and
their functional survival time was significantly (P <
.0001) better than that of the other xenografts (Table
II). Xenograft failure occurred in 4 lungs belonging to
group II and in all group III and IV lungs (P < .0001).
The PVR and CaO2 – CvO2 of group I xenografts were
significantly better than those observed in the other
xenografts (Fig 4).
Group I left lung xenografts were always normal in
histologic and immunohistologic appearance at the end
of the perfusions, showing only isolated areas of alve-
olar edema. In contrast, all xenografts belonging to the
other groups showed severe alveolar edema but no
thrombotic events within the lung capillary beds (Fig
5); on immunohistologic examination, their alveolar
capillaries stained weakly with C3 (Fig 6).
Effects of the in situ, in vitro, and ex vivo experi-
ments on the human blood. The hematocrit levels
remained stable through the study periods in the preper-
fused lung and a -Gal column human blood but in-
creased significantly in the samples of the preperfused
spleen (Fig 7). Except for the white blood cells (Fig 8),
the human blood reperfusing group I lung xenografts
showed a significant lower decline of coagulation fac-
The Journal of Thoracic and
Cardiovascular Surgery
Volume 116, Number 5
Macchiarini et al   837
Fig 3. Representative western blot analysis of 3 independent experiments, analysis of the reactivity of human
serum before and after natural antibody immunoadsorption. Porcine aortic endothelial cell membrane extracts were
separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis, blotted onto polyvynillidene difluoride
and then stained as follows: lane 1, human serum, before depletion; lane 2, human serum, after in vitro depletion
on the a -Gal column; lane 3, human serum, before depletion; lane 4, human serum, after in situ perfusion of the
right lung; lane 5, monoclonal anti-a -Gal antibody. Molecular weight standards are shown on the left. Between
lanes 4 and 5 is illustrated the position of the bands that disappear after absorption in lanes 2 and 4. Antibody bind-
ing was revealed with antihuman IgG (A), IgM (B), or antimouse Ig (lane 5) alkaline phosphatase–conjugated sec-
ondary reagents.
Table II. Functioning survival time of the ex vivo perfused pig lungs
Functioning xenografts 
Xenograft survival (min) at the end of experiments
Type of absorption Median Range Number %
Right lung 300 240-360 6/6 100
Liver 150 90-180 2/6 33
Spleen 60 30-120 0/6 0
a -Gal column 105 30-120 0/6 0
Xenograft failure was defined as such when the ex vivo lung perfusion was associated with no gas exchange, severe pulmonary hypertension, and gross evidence of
pulmonary hemorrhage and edema.
tors (Table III), total circulating immunoglobulins
(Table IV), and activation of CH100 (Fig 9), membrane
attack complex (Fig 10), and hemolysis (Fig 11) than
did groups II, III, and IV during the study period.
Discussion
Preformed natural antibodies of both IgM and IgG
isotypes in human beings and Old World monkeys rep-
resent a major hurdle to discordant xenotransplantation
by initiating hyperacute rejection within minutes to
hours.6 Recent investigations have defined the main
antigenic target of human xenoantibodies as being the
terminal galactose residue in a 1-3 linkage Gala (1-
3)Gal,17,18 which is densely distributed along the vas-
cular endothelium of all porcine organs, including the
heart, lung, liver, kidney, and pancreas.19 One percent
of the human B cells are capable of producing anti-a -
Gal antibodies,14 and approximately 80% of the pre-
formed human antipig xenoantibodies are specific for
this epitope.20 Unsurprisingly, and in analogy with
ABO-incompatible21 and HLA-incompatible and
hyperimmunized allotransplants,22 removal of anti-a -
Gal natural antibodies from the primate circulation by
plasma exchange,21 pig donor organ absorption,7,23-26
or column immunoabsorption15,27 has been investigat-
ed. Despite some limitations of each of these approach-
es,5 increasing experimental and clinical evidence sug-
gests that these antibody-depleting procedures can
prolong pig to primate organ xenograft survival from
minutes to several days.
Selective column immunoabsorption offers a more
clinically attractive option than pig donor organ perfu-
sion to remove xenoantibodies from the circulation of
xenograft recipients because of its hemodynamic sta-
bility27 and limited effects on the coagulation system
and plasma protein levels.15 In addition, the possibility
of repeated use in the peritransplantation period makes
it more practical. However, the 2 antibody-depleting
strategies prolong pig kidney27 xenograft survival
equally. In this study the amount of anti-a -Gal removed
by column immunoabsorption was significantly higher
than that removed by pig lung perfusion (90% ± 3% vs
78% ± 4%, respectively). Although the reduction of
anti-a -Gal was incomplete, both techniques were able
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Fig 4. A, PVR at baseline (time 0) and at specific intervals after perfusion of pig left lung with the in situ (pig organ)
or in vitro (a -Gal column) preperfused human blood. The PVR of the left lung was significantly lower when the
human blood was preperfused through the right lung than when it was preperfused through the liver (P = .0002),
spleen (P = .001), or a -Gal column (P < .0001). The normal PVR values observed in pig lungs perfused with auto-
genic blood are <0.25 mm Hg/mL/min according to Macchiarini, Mazmanian, and Oriol.3 B, Oxygen extraction,
reflected by CaO2 – CvO2 (AVO2) of pig lung at specific intervals after perfusion of pig left lung with the in situ (pig
organ) or in vitro (a -Gal column) previously perfused human blood. Hemoglobin concentrations to calculate CaO2 –
CvO2 were normalized for the observed hematocrit. CaO2 – CvO2 of pig left lung perfused with human blood preper-
fused through the right lung was significantly better than with the other preperfusion strategies (liver, P < .0001;
spleen, P = .008; a -Gal column, P = .0007). The normal CaO2 – CvO2 values observed in pig lung perfused with auto-
genic blood are between 20 and 25 mL oxygen/100 mL. Data are expressed as mean ± standard deviation (error bars).
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Fig 5. Histologic appearance of pig left lung perfused with
the human blood preperfused in situ through pig spleen. The
alveolar capillaries are dilated and packed with red blood
cells but without intravascular thrombi. The edema is charac-
terized by a proteinaceous fluid within the alveolar lumens.
(Original magnification · 530.)
Fig 8. Human white blood cells before (B) and after (A)
the in situ or in vitro absorptions and after 10 and 60 min-
utes of the ex vivo left lung perfusion. The decline in
white blood cells in the human blood absorbed through pig
liver was significantly lower than that observed in blood
absorbed through right lung (P = .04), spleen (P = .0005),
and a -Gal column (P = .02). Data are expressed as mean
± standard deviation (error bars) of the experiments and
normalized for the observed hematocrit. Baseline white
blood cells were 8983 ± 844 cells/mm3, 5600 ± 400 cells/
mm3, 6500 ± 900 cells/mm3, and 7083 ± 384 cells/mm3 for
the liver, spleen, a -Gal column, and right lung groups,
respectively.
Fig 7. Hematocrit before and after the in situ or in vitro
absorptions and after 10 and 60 minutes of the ex vivo left
lung perfusion with human blood. Data are expressed as
mean ± standard deviation (error bars). The human blood
absorbed through spleen displayed a significantly higher
hematocrit increase during the study periods than that
absorbed with liver (P = .01) or a -Gal column (P = .03).
Fig 6. Immunofluorescence with antihuman C3. The strong
deposition usually observed after perfusion of pig lung with
untreated human blood (A, hyperacute rejection) is compared
with the weak deposition (B) observed along the alveolar
capillaries of an ex vivo pig lung perfused with human blood
absorbed through pig liver. (Original magnification · 200.)
to prevent the formation of platelet and fibrin thrombi
occluding the alveolar-capillary vessels of the ex vivo
perfused pig lungs, the classic sign of hyperacute lung
rejection in pig to human xenotransplants.2,3 This con-
firms in vitro and in vivo studies28 proving that com-
plete xenoantibody absorption is unnecessary to prevent
hyperacute rejection. It may be that the fraction of anti-
a -Gal xenoantibodies that were not absorbed by either
strategy are of low affinity and do not appear to play a
pivotal role in the genesis of lung hyperacute rejection.
However, because only the in situ pig donor lung per-
fusion completely prevented xenograft failure of a sub-
sequently ex vivo working pig lung, it is not hazardous
to postulate that the a -Gal barrier is not the only factor
responsible for the hyperacute lung rejection in the pig
to human combination. Other non-a -Gal xenoantibod-
ies, absorbed by the pig donor lung but not by the a -Gal
column, may react against non-a -Gal epitope xenoanti-
gens expressed on pig lung and induce xenograft dys-
function on ex vivo reperfusion. This assumption is
endorsed by the Western blot analysis, in which anti-
bodies to the highly a -galactosylated major protein
with molecular weight of 135 kDa were removed by
both a -Gal column and pig organ perfusion, and this is
in line with previous studies.29 However, antibodies
against other proteins with lower molecular weight
were depleted by pig donor lung and, to a lesser extent,
by liver perfusion but were not removed by the a -Gal
column. This finding is in accordance with previous
Western blot analysis performed after pig liver30 perfu-
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Table III. Modifications of human coagulation factors during the in situ, in vitro, and ex vivo experiments
Timing Right lung Liver Spleen a -Gal column
Platelets (· 1000/mm3) Before 465 ± 41 600 ± 43 494 ± 5 298 ± 56
After 311 ± 40 339 ± 46 312 ± 12 232 ± 69
10 min 314 ± 42 263 ± 19 265 ± 86 110 ± 82
60 min 300 ± 52 230 ± 12 224 ± 17 102 ± 72
APTT (sec) Before 37 ± 3 40 ± 5 47 ± 12 38 ± 4
After 42 ± 5 52 ± 10 75 ± 25 62 ± 30
10 min 47 ± 5 61 ± 18 107 ± 17 74 ± 36
60 min 54 ± 6 65 ± 23 120 ± 12 98 ± 13
PTT (sec) Before 38 ± 3 43 ± 2 41 ± 4 67 ± 7
After 43 ± 2 55 ± 7 52 ± 8 53 ± 13
10 min 50 ± 2 62 ± 5 63 ± 20 54 ± 11
60 min 54 ± 3 67 ± 6 75 ± 33 79 ± 9
Fibrinogen (g/L) Before 2.8 ± 0.1 2.3 ± 0.1 2.5 ± 0.2 2.5 ± 0.4
After 2.1 ± 0.1 1.3 ± 0.1 1.6 ± 0.3 1.2 ± 0.4
10 min 1.5 ± 0.1 0.9 ± 0.1 0.8 ± 0.3 0.9 ± 0.3
60 min 1.4 ± 0.1 0.8 ± 0.1 0.8 ± 0.3 0.8 ± 0.3
Data are expressed as mean ± standard deviation. APTT, activated partial thromboplastin time; PT, prothrombin time. Comparison between values before and after
in situ (pig donor organs) or in vitro ( a -Gal column) absorption and after 10 and 60 minutes of ex vivo perfusion experiments.
Table IV. Modification of total human immunoglobulins during the in situ, in vitro and ex vivo experiments
Timing Right lung Liver Spleen a -Gal column
IgG (g/L) Before 23 ± 1 29 ± 3 36 ± 10 17 ± 5
After 18 ± 1 16 ± 3 10 ± 2 15 ± 3
10 min 18 ± 1 12 ± 2 8 ± 3 12 ± 3
60 min 17 ± 2 11 ± 1 7 ± 2 10 ± 3
IgM (g/L) Before 2 ± 0.1 3.7 ± 1 6.4 ± 1 1.7 ± 0.4
After 1.6 ± 0.1 2 ± 0.3 1.5 ± 0.5 1.4 ± 0.3
10 min 1.6 ± 0.1 1.6 ± 0.3 1 ± 0.7 1.2 ± 0.3
60 min 1.6 ± 0.1 1.3 ± 0.2 1 ± 0.5 1.1 ± 0.3
IgA (g/L) Before 6.8 ± 1 6.1 ± 1 6.4 ± 2 5.9 ± 1
After 5 ± 0.5 3.4 ± 1 1 ± 1 4 ± 1
10 min 4.6 ± 1 3 ± 0.6 1 ± 1 3 ± 1
60 min 4.5 ± 1 2.3 ± 0.4 1 ± 0.4 3 ± 1
Data are expressed as mean ± standard deviation. Comparison between values of immunoglobulin before and after in situ (pig donor organs) or in vitro ( a -Gal col-
umn) absorption and after 10 and 60 minutes of ex vivo perfusion experiments.
sion and suggests that antibody depletion through pig
donor organ perfusion removes antibodies involved in
the genesis of hyperacute rejection that are not removed
after the a -Gal column immunoadsorption.
Lung, liver, and spleen in situ absorbed almost equal
percentages of human a -Gal xenoantibodies from
human blood. However, when absorption rates were
normalized for pig organ weight and natural a -Gal
xenoantibodies levels before perfusion, the lung
absorbed 1.5 and 17 times more xenoantibodies per
gram of tissue than did spleen and liver, respectively
(data not shown). Comparing the immunoabsorptive
capacity of lung tissue observed in this study it appears
that the lung is, from a quantitative viewpoint, a more
potent a -Gal absorbent than liver or spleen. From a
qualitative point of view, the plasma and cellular mod-
ifications of the human blood reperfusing the ex vivo
lungs were of significantly less clinical relevance when
pig lung was used to deplete anti-a -Gal antibody from
the human blood than with other strategies or other
organ perfusion.25,27 In effect, pig lung perfusion
caused significantly less depletion of coagulation pro-
teins, complement activation, and therefore hemolysis,
rendering it a more clinically acceptable intervention,
especially in light of recent in vivo evidence27 demon-
strating that removal of xenoantibody alone, without
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Fig 9. CH100 in human plasma before (B) and after (A) the in
situ or in vitro absorptions and after 10 and 60 minutes of the
ex vivo left lung perfusion. Data are expressed as mean ±
standard deviation (error bars). The CH100 of the human
plasma absorbed through pig right lung declined significantly
less than that absorbed through the liver (P = .02), spleen
(P < .0001), or a -Gal column (P = .02). Reference physio-
logic value is <70 CH100 U/mL.
Fig 10. Membrane attack complex (SC5b-9) activation in the
human serum before (B) and after (A) the in situ or in vitro
absorptions and after 10 and 60 minutes of the ex vivo left
lung perfusion. Data are expressed as mean ± standard devi-
ation (error bars). The difference between the lung and the
other absorption methods was significantly different (P =
.0001). Reference physiologic value is 0 µg/mL.
Fig 11. Hemolysis in human plasma before (B) and after (A)
the in situ or in vitro absorptions and after 10 and 60 minutes
of the ex vivo left lung perfusion. Data are expressed as mean
± standard deviation (error bars). The hemolysis of the
human plasma absorbed through pig right lung was signifi-
cantly lower than that absorbed through liver (P = .04),
spleen (P = .018), or a -Gal column (P = .001). Reference
physiologic value is <150 mg Hb/100 mL).
specific complement intervention, prevents hyperacute
rejection of a transplanted pig kidney.
The ex vivo lung xenografts perfused with human
blood and preperfused through pig right lung were
functionally working and histologically intact for
longer than 5 hours on reperfusion. In contrast, all but
2 liver preperfused xenografts lost their function well
before this time, and their histologic examination
always showed pulmonary congestion and severe alve-
olar edema. Because all harvesting procedures were
performed in a similar fashion, the interpretation of this
is that only the absorption of human blood through pig
donor right lung prevents hyperacute rejection for at
least 5 hours. Whether this is due to a higher immuno-
absorptive capacity or, more likely, to organ-specific
(non-a -Gal) xenoantibody depletion by lung tissue
remains to be determined. This last explanation is more
realistic because in our laboratory with a pig to goat
orthotopic lung xenotransplantation model (unpub-
lished results), cross-perfusion of goat blood through
right pig donor lung totally prevented the hyperacute
rejection of the implanted left pig lung, even after
clamping of the contralateral pulmonary artery. This
observation is even more important if we take into
account that both species do not have anti-a -Gal anti-
bodies in their circulation and that pig lungs orthotopi-
cally implanted into goats show a hyperacute rejection
similar to that observed in the ex vivo pig to human
lung model.3
The results of this study provide evidence that spe-
cific depletion of anti-a -Gal antibodies alone incom-
pletely protects pig lung from hyperacute rejection. We
speculate that the more complete prevention of this
rejection afforded by pig lung preperfusion is related to
the removal of other non-a -Gal antibodies.
We thank U. Galili for the kind gift of the anti-a -Gal mono-
clonal antibody. We also express our gratitude for the excel-
lent technical assistance of Chantal Verriest, Rémi Burel,
Pascal Gusmini, Hegésippe Langouste, Bruno Baudet, Aline
Perrin, and Sylvie Planté. The photographic contribution of
Denis Petraz is acknowledged. Special thanks are directed to
Drs Guiard Jean, Poutiers Philippe, and Bap Charly for their
help in supervising the human blood units.
R E F E R E N C E S
1. Platt JL, Vercelotti GM, Dalmasso AP. Transplantation of discor-
dant xenografts: A review of progress. Immunol Today
1990;11:450-6.
2. Pierson RN, Kasper-Konig W, Tew DN, Young VK, Dunning JJ,
Horsley J, et al. Hyperacute lung rejection in a pig-to-human
transplant model. Transplantation 1997;63:594-603.
3. Macchiarini P, Mazmanian GM, Oriol R. Ex-vivo lung model of
pig to human hyperacute xenograft rejection. J Thorac
Cardiovasc Surg 1997;114:315-25.
4. Daggett CW, Yeatman M, Lodge AJ, Chen EP, Trigt VP, Byrne
GW, et al. Swine lungs expressing human complement-regulato-
ry proteins are protected against pulmonary dysfunction in a
human plasma perfusion model. J Thorac Cardiovasc Surg 1997;
113:390-8.
5. Hoopes CW, Platt JL. Molecular strategies for clinical xenotrans-
plantation in cardiothoracic surgery. Semin Thorac Cardiovasc
Surg 1996;8:156-74.
6. Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH.
Immunopathology of hyperacute xenograft rejection in a swine-
to-primate model. Transplantation 1991;52:214-20.
7. Daggett CW, Yeatman M, Lodge AJ, Chen EP, Linn SS, Gullotto
C, et al. Total respiratory support from swine lungs in primate
recipients. J Thorac Cardiovasc Surg 1998;115:19-27.
8. Pierson RN, Pino-Chavez G, Young VK, Kaspar-Konig W, White
DK, Wallwork J. Expression of human decay accelerating factor
may protect pig lung from hyperacute rejection by human blood.
J Heart Lung Tranplant 1997;16:231-9.
9. Pierson RN 3d, Kaspar-König W, Tew DN, Young VK, Braidley
PC, White DJ, et al. Profound pulmonary hypertension characteris-
tic of pig lung rejection by blood is mediated by xenoreactive anti-
bodies independent of complement. Transplant Proc 1995;27: 274.
10. Macchiarini P, Oriol R, Mazmanian M, Dartevelle P. Lung xeno-
transplantation: lessons learned and future perspectives. In:
Franco KL, Putman JB. Advances in thoracic surgery. Hamilton,
Ontario: BC Decker; 1998. p. 404-14.
11. Korchagina EY, Bovin NV. [Synthesis of spacered trisaccharides
with blood group specificities A and B, their fragments and struc-
tural analogs.] Bioorg Khim 1992;18:283-98.
12. Bovin N, Korchagina E, Zemlyanukhina T, Byramova N,
Galanina O, Zemlyakov A, et al. Synthesis of polymeric neogly-
coconjugates based on N-substituted polyacrylamide. Glycocon-
jugate J 1993;10:142-51.
13. Bovin NV. Sugar-polyacrylamide conjugates as probes for cell
lectins. In: Gabius HJ, Gabius S. Lectins and glycobiology.
Berlin: Springer-Verlag; 1993. p. 23-31.
14. Galili U. Interaction of the natural anti-Gal antibody with a -
galactosyl epitopes: a major obstacle for xenotransplantation.
Immunol Today 1993;14:480-2.
15. Rieben R, van Allmen E, Korchagina EY, Nydegger UE,
Neethling FA, Kujundzic M, et al. Detection, immunoabsorption,
and inhibition of cytotoxic activity of anti-a Gal antibodies using
newly developed substances with synthetic Gala 1-3Gal disac-
charide epitopes. Xenotransplantation 1995;2:98-106.
16. Azimzadeh A, Wolf K, Thibaudeau D, Cinqualbre J, Soulillou JP,
Anegon I. Comparative study of target antigens for primate
xenoreactive natural antibodies in pig and rat endothelial cells.
Transplantation 1997;64:1166-74.
17. Sandrin MS, Vaughan HA, Dabrowski PL, McKenzie IF. Anti-pig
antibodies in human serum react predominantly with Gala (1,3)Gal
epitopes. Proc Natl Acad Sci U S A 1993;90:11391-5.
18. Good AH, Cooper DK, Malcolm AJ, Ippolito E, Koren E,
Neethling FA, et al. Identification of carbohydrate structures that
bind human anti-porcine antibodies: implications for discordant
xenografting in humans. Transplant Proc 1992;24:559-62.
19. Oriol R, Ye Y, Koren E, Cooper DK. Carbohydrate antigens of
pig tissues reacting with human natural antibodies as potential
targets for hyperacute vascular rejection in pig-to-man organ
xenotransplantation. Transplantation 1993;56:1433-42.
842 Macchiarini et al The Journal of Thoracic and
Cardiovascular Surgery
November 1998
20. Parker W, Bruno D, Holzknecht ZE, Platt JL. Characterization
and affinity isolation of xenoreactive human natural antibodies. J
Immunol 1994;153:3791-803.
21. Alexandre GP, Gianello P, Latinne D, Carlier M, Dewalle A, Von
Obbergh L, et al. Plasmapheresis and splenectomy in experimen-
tal renal xenotransplantation. In: Hardy MA, editor. Xenografts
25. New York. Elsevier Science; 1989. p. 259-66.
22. Palmer A, Welsh K, Gjorstrup P, Bewick M, Thick M. Removal
of anti-HLA antibodies by extracorporeal immunoabsorption to
enable renal transplantation. Lancet 1989;1:10-2.
23. Cotterell AH, Collins BH, Parker W, Harland RC, Platt JL. The
humoral immune response in humans following cross-perfusion
of porcine organs. Transplantation 1995;60:861-8.
24. Chari RS, Collins BH, Mages JC, DiMaio JC, Kirk AD, Harland
RC, et al. Brief report: treatment of hepatic failure with ex vivo
pig-liver perfusion followed by liver transplantation. N Engl J
Med 1994;331:234-7.
25. Azimzadeh A, Meyer C, Waiter H, Beller JP, Chenard-Neu MP,
Kieny R, et al. Removal of primate xenoreactive natural antibod-
ies by extracorporeal perfusion of pig kidneys and livers.
Transplant Immunol 1998;6:13-22.
26. Rydberg L, Bjorck S, Hallberg E, Magnusson S, Sumitran S,
Samuelsson BE, et al. Extracorporeal (“ex vivo”) connection of
pig kidneys to humans. II. The anti-pig antibody response.
Xenotransplantation 1996;3:340-53.
27. Xu Y, Sablinski T, Gianello P, Bailin M, Monroy R, Kozlowski T,
et al. Removal of anti-porcine natural antibodies from human and
nonhuman primate plasma in vitro and in vivo by Gala 1-3Galb 1-
4b Glc-X immunoaffinity column. Transplantation 1998;65:172-9.
28. Welsh KI, Taube DH, Thick M, Palmer A, Stevens N, Binns RM.
Human antibodies to pig determinants and their association with
hyperacute rejection of xenografts. In: Cooper DK, Kemp E,
Reemtsma K, White DJ. Xenotransplantation. Berlin: Springer;
1991. p. 501-10.
29. Cooke SP, Hederer J, Pearson D, Savage CO. Characterization of
human IgG-binding xenoantigens expressed by porcine aortic
endothelial cells. Transplantation 1995;60:1274-84.
30. Atia N, Camoin L, Duflos G, Chereau C, Malassagne B,
Filipponi F, et al. Porcine serotransferrin: a major xenoantigen
recognized by human natural IgG. Proceedings of the 4th
International Congress for Xenotransplantation. Nantes. 1997,
abstract 076.
Discussion
Dr David J. Sugarbaker (Boston, Mass). It appears as
though you have indeed moderated the hyperacute response.
To what extent is this simply a washout of the immunologic
factors that are responsible for that response? In other words,
are you not with your preperfusion simply washing out, to a
certain degree, complement and other elements that are the
principal components of the hyperacute response?
Dr Macchiarini. I can only speculate, but I think that the
reason that the lung acts as an effective protection is simply
that xenoactive antibodies are fixed on the lung surface and
therefore do not activate the complement after the ex vivo
reperfusion. So far, the only recognized antibodies are the
anti-a -Gal antibodies. We were able to demonstrate that
there are other antibodies, but I do not at this stage know
exactly what these other types of antibodies are.
Dr Axel Haverich (Hannover, Germany). I congratulate
you on this presentation and elegant study. It may be of sig-
nificant importance to follow up on these experiments in
terms of potential future developments in transgenic or
knockout preparations for xenotransplantation. My question
is whether you are able to identify—not only detect, but also
identify—other antigens or genes related to the xenoreactive
antibody response in human beings.
Also, do you not think that for further experiments it would
be important to change the model in terms of the pig to pri-
mate model so that you would also be able to look at the
delayed xenoresponse and cellular rejection?
Dr Macchiarini. In response to the first question, yes we
can. There is a simple method, but we need to go back and
remake the ex vivo lung perfusion. You do the same experi-
ments, but you have to lyophilize lungs to see what kind of
antibodies were fixed on the lung and eliminate them from
the other population of potential xenoantibodies present in
the circulation. We are currently planning to do that.
With respect to the second question, such a change indeed
would be great; however, there is an economic problem
because nonhuman primates are expensive, and I think that
the lung as opposed to the heart is at the early stage of this
type of investigation. As you know better than I, with a trans-
genic pig you can afford partial protection from hyperacute
rejection, but it still takes place after a few days if you use a
transgenic pig for complement regulatory proteins.
Dr Chris T. Salerno (Minneapolis, Minn). There has been
some suggestion that in lung xenotransplantation the associ-
ated increase in PVR produces some endothelial cell damage
that leads to activation of the alternative complement path-
way. Did you look at all at activation of the alternative com-
plement pathway?
Dr Macchiarini. Not in this study, but in a previous study
we demonstrated that the first pathway of the complement
activation is classic. You may have alternative pathways in
the lung—not in the pig to human models but, for instance, in
the rat to human models.
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